Coloplast stock faces lower 2030 growth target after guidance reset
Published on 11/11/2026 at 03:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGrowth ambitions and near-term plan
- Coloplast lowered its 2030 organic growth ambition to 5% to 7% a year.
- Fiscal 2026/27 guidance calls for organic revenue growth of 5% to 7% and an EBIT margin of around 25%.
- Investment increases and inflation remain key factors behind the revised outlook.
Coloplast revised its long-term financial ambition on November 3, 2026, lowering its targeted annual organic revenue growth through 2030 to 5% to 7% from 7% to 8% previously. The medical technology group also set fiscal 2026/27 guidance for organic revenue growth of 5% to 7% and an EBIT margin of around 25%, according to Coloplast's announcement.
A more cautious long-term target
The revised ambition reflects changes in the external environment, including reimbursement changes in US biologics, healthcare reform-related pricing pressure and inflation. Coloplast now expects an EBIT margin in the mid-20% range in constant currencies over the period and return on invested capital of around 20% in fiscal 2029/30, compared with a previous ambition of more than 20%.
The company said its market assumptions include 4% to 5% industry growth, continued momentum in Chronic Care and mid- to high-single-digit growth in Interventional Urology. Wound and Tissue Repair is expected to deliver mid-single-digit growth, as the US reimbursement change weighs on biologics expansion.
Investment and cost pressure
Coloplast plans to increase spending on innovation and selected commercial areas, especially in US Chronic Care, parts of Europe, emerging markets and Interventional Urology. A broad Funding the Journey program is intended to free up around DKK 500 million for redeployment and to offset part of the cost pressure.
For fiscal 2026/27, Coloplast expects reported revenue growth in Danish kroner of 7% to 9%, including an estimated two-percentage-point currency benefit. Inflation affecting raw materials and freight is expected to remain a headwind, while special items related to the program are forecast at around DKK 200 million.
Coloplast's healthcare portfolio
Coloplast is a Denmark-based global healthcare company focused on products and services for people with intimate healthcare needs. Its business areas include Ostomy Care, Continence Care, Voice and Respiratory Care, Wound and Tissue Repair, and Interventional Urology, as described on the company's investor relations page. The portfolio gives the group exposure to several specialist healthcare niches across global markets.
Coloplast company facts
- Company: Coloplast A/S
- ISIN: DK0060448595
- Headquarters: Humlebaek, Denmark
Investors are now focused on whether Coloplast can convert higher spending into renewed growth while protecting margins against inflation and reimbursement pressure. The next updates on execution will be important for assessing the credibility of the revised long-term targets.
European investors can follow broader developments through the Euro Stoxx 50 market environment.
More news and analyses on Coloplast stock.
